Lightner AL, McKenna NP, Alsughayer A, et al. - In this retrospective review, adult patients with Crohn disease who received an antitumor necrosis factor, vedolizumab, ustekinumab, or no biologic therapy within 12 weeks of a major abdominal operation were compared regarding the rates of 30-day postoperative overall infectious complications and intra-abdominal septic complications. Among 712 included patients, 272 patients were exposed to an antitumor necrosis factor agents, 127 to vedolizumab, 38 to ustekinumab, and 275 to no biologic therapy within the 12 weeks before an abdominal operation. Outcomes revealed no increase in the overall rate of total infectious complications or intra-abdominal septic complications with respect to preoperative exposure to a particular class of biologic. Increased rates were observed in correlation with combination immunosuppression of biologic therapy with corticosteroids and previous abdominal resection.